ISR Articles

  1. Small Molecule Drug Substance Pandemic Complications 1/14/2022

    Over the past two years, ISR has asked respondents to its annual small molecule drug substance benchmarking surveys whether they encountered pandemic related complications with their outsourced manufacturing. The data show it was slightly more common for small molecule API outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020.

  2. Small Molecule Sterile Injectable Outsourcing Volume 11/15/2021

    In Q2 2021, ISR asked 57 respondents how many small molecule sterile injectable products they have on the market, the proportion of sterile injectable manufacturing that is outsourced and the number of CDMOs they use to complete the work. On average, respondents have 3.4 marketed biologic products, of which 67% of drug product manufacturing is outsourced and use an average of 3.3 CDMOs.  To learn how these proportions are predicted to change in the next five years, follow the link to the Sterile Injectable Market Outlook report preview. 

  3. Old Dog, New Tricks: How The Pharma Industry Is Innovating With Existing Technologies 11/2/2021

    Innovation in clinical technologies sometimes comes in the shape of disruptive new technologies and, other times, as a series of incremental changes and improvements. New data is revealing positive changes, and existing tech solutions are now being used in new ways to facilitate remote engagement, analyze data, and conduct hybrid clinical trials.

  4. Do Strategic Partnerships Meet Outsourcers Expectations? 10/18/2021

    ISR’s CDMO Outsourcing Models report dives into three approaches to contracting manufacturing work, the motivations behind them, and which methods earn the greatest satisfaction among users.

  5. Manufacturing Costs For Small Molecule Development Work 10/18/2021

    In Q3 2020, ISR asked 49 respondents to allocate the costs of development work and clinical trial materials for outsourced small molecule drugs. The data show that API Manufacturing and Drug Product Manufacturing and Process Development capture similar proportions of outsourced spend at this stage. 

  6. Outsourcer Engagement Preferences – No Love For Linkedin 10/1/2021

    Despite the pandemic shifting away from in-person interaction, the data shows it has not had lasting impact on the preference for face-to-face communication with outsourcers.

  7. Top 5 Oral Dosage Forms By Expenditure 9/18/2021

    In Q2 2021, ISR asked 100 outsourcers of oral dose manufacturing to allocate the proportion of their company’s outsourced expenditure by dosage form. The data show that traditional tablets currently account for the largest proportion of spend, followed by controlled release tablets and immediate release tablets. However, respondents predict some of the current spend on tablets will shift to capsules five years from now. To learn more, follow the link to the Oral Dosage Forms Market Outlook report preview.

  8. Is OSD Becoming More Complicated? 9/8/2021

    Are CDMOs evaluated on the same metrics for simple and complex oral dose manufacturing projects? Data from ISR’s new report provides insight on these questions and more.

  9. Outsourcing Drivers For Small Molecule Manufacturing 7/6/2021

    ISR’s recent survey of small molecule outsourcers found that the majority of respondents outsource for one of two reasons: for all of their manufacturing needs, or to augment their internal manufacturing capacity.

  10. Manufacturing Expenditure By Activity 7/6/2021

    Learn about the competitive activities that clinical manufacturing sponsors spend the most money on, providing some insight into the clinical manufacturing market and where it’s heading.